Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: Impact of nonalcoholic fatty liver disease

References

• Al-Gayyar MM, Eissa LA, Rabie AM, El-Gayar AM. (2007). Measurements of oxidative stress status and antioxidant activity in chronic leukaemia patients. J Pharm Pharmacol, 59, 409–417.
   PubMed Web of Science ®Google Scholar
• Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. (2005). Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology, 42, 44–52.
   PubMed Web of Science ®Google Scholar
• Begriche K, Igoudjil A, Pessayre D, Fromenty B. (2006). Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it. Mitochondrion, 6, 1–28.
   PubMed Web of Science ®Google Scholar
• Brown JM, Chung S, Sawyer JK, Degirolamo C, Alger HM, Nguyen TM, Zhu X, Duong MN, Brown AL, Lord C, Shah R, Davis MA, Kelley K, Wilson MD, Madenspacher J, Fessler MB, Parks JS, Rudel LL. (2010). Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol, 30, 24–30.
   PubMed Web of Science ®Google Scholar
• Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A. (2006). Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot study. Aliment Pharmacol Ther, 23, 1143–1151.
   PubMed Web of Science ®Google Scholar
• Carter-Kent C, Zein NN, Feldstein AE. (2008). Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: Implications for treatment. Am J Gastroenterol, 103, 1036–1042.
   PubMed Web of Science ®Google Scholar
• Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldalamacchia G, Finelli C, Conca P, Contaldo F, Pasanisi F. (2005). Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab, 49, 289–295.
   PubMedGoogle Scholar
• Copaci I, Micu L, Voiculescu M. (2006). The role of cytokines in non-alcoholic steatohepatitis: A review. J Gastrointestin Liver Dis, 15, 363–373.
   PubMedGoogle Scholar
• De Ley M, de Vos R, Hommes DW, Stokkers P (2007). Fish oil for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, 17: CD005986.
   Google Scholar
• Deen D. (2004). Metabolic syndrome: Time for action. Am Fam Physician, 69, 2875–2882.
   PubMed Web of Science ®Google Scholar
• Duvnjak M, Lerotic I, Barsic N, Tomasic V, Virovic Jukic L, Velagic V. (2007). Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol, 13, 4539–4550.
   PubMed Web of Science ®Google Scholar
• El-Assal O, Hong F, Kim WH, Radaeva S, Gao B. (2004). IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol, 1, 205–211.
   PubMed Web of Science ®Google Scholar
• El-Mesery M, Al-Gayyar M, Salem H, Darweish M, El-Mowafy A. (2009). Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): Implications of CRP and lipid peroxides. Cell Div, 4, 6.
   PubMed Web of Science ®Google Scholar
• Ford ES. (2005). Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care, 28, 2745–2749.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18, 499–502.
   PubMed Web of Science ®Google Scholar
• García-Galiano D, Sánchez-Garrido MA, Espejo I, Montero JL, Costán G, Marchal T, Membrives A, Gallardo-Valverde JM, Muñoz-Castañeda JR, Arévalo E, De la Mata M, Muntané J. (2007). IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg, 17, 493–503.
   PubMedGoogle Scholar
• Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P. (2006). Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol, 44, 1167–1174.
   PubMed Web of Science ®Google Scholar
• Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. (1997). Antibodies to tumor necrosis factor α attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology, 26, 1530–1537.
   PubMed Web of Science ®Google Scholar
• Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. (2006). Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology, 43, 474–484.
   PubMed Web of Science ®Google Scholar
• Mensink RP, Plat J, Schrauwen P. (2008). Diet and nonalcoholic fatty liver disease. Curr Opin Lipidol, 19, 25–29.
   PubMedGoogle Scholar
• Paschos P, Paletas K. (2009). Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia, 13, 9–19.
   PubMed Web of Science ®Google Scholar
• Poniachik J, Csendes A, Díaz JC, Rojas J, Burdiles P, Maluenda F, Smok G, Rodrigo R, Videla LA. (2006). Increased production of IL-1α and TNF-α in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine, 33, 252–257.
   PubMedGoogle Scholar
• Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. (2005). Nonalcoholic steatohepatitis: Recent advances from experimental models to clinical management. Clin Biochem, 38, 203–217.
   PubMed Web of Science ®Google Scholar
• Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Müller B. (2005). Central fat excess in polycystic ovary syndrome: Relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab, 90, 6014–6021.
   PubMed Web of Science ®Google Scholar
• Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F. (2006). ω-3 Polyunsaturated fatty acids: A pilot trial in nonalcoholic fatty liver disease. J Hepatol, 44:S264.
   Google Scholar
• Targher G, Arcaro G. (2007). Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis, 191, 235–240.
   PubMed Web of Science ®Google Scholar
• Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S. (2002). Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology, 122, 274–280.
   PubMed Web of Science ®Google Scholar
• Wang PW, Hsieh CJ, Psang LC, Cheng YF, Liou CW, Weng SW, Chen JF, Chen IY, Li RH, Eng HL. (2008). Fatty liver and chronic inflammation in Chinese adults. Diabetes Res Clin Pract, 81, 202–208.
   PubMedGoogle Scholar
• Weatherill AR, Lee JY, Zhao L, Lemay DG, Youn HS, Hwang DH. (2005). Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol, 174, 5390–5397.
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. (2008). Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol, 103, 1372–1379.
   PubMed Web of Science ®Google Scholar